Nateglinide

 Nateglinide (INN, trade name Starlix) is a drug for the treatment of type 2 diabetes. Nateglinide was developed by Ajinomoto, a Japanese company and sold by the Swiss pharmaceutical company Novartis.

Nateglinide
Nateglinide.svg
Clinical data
Trade namesStarlix
AHFS/Drugs.comMonograph
MedlinePlusa699057
License data
  • EU EMA: by INN
  • US FDA: Nateglinide
Routes of
administration		Oral
ATC code
  • A10BX03 (WHO)
Legal status
Legal status
  • UK: POM (Prescription only)
  • US: ℞-only
Pharmacokinetic data
Protein binding98%
Elimination half-life1.5 hours
Identifiers
IUPAC name
  • (2R)-2-({[trans-4-(1-methylethyl)cyclohexyl]carbonyl}amino)-3-phenylpropanoic acid
CAS Number
  • 105816-04-4 check
PubChem CID
  • 60026
IUPHAR/BPS
  • 6833
DrugBank
  • DB00731 check
ChemSpider
  • 10482084 check
UNII
  • 41X3PWK4O2
KEGG
  • D01111 ☒
ChEBI
  • CHEBI:31897 ☒
ChEMBL
  • ChEMBL286559 ☒
CompTox Dashboard (EPA)
  • DTXSID9040687 Edit this at Wikidata
ECHA InfoCard100.170.086 Edit this at Wikidata
Chemical and physical data
FormulaC19H27NO3
Molar mass317.429 g·mol−1
3D model (JSmol)
  • Interactive image
SMILES
  • O=C(N[C@H](Cc1ccccc1)C(O)=O)[C@H]2CC[C@@H](CC2)C(C)C
InChI
  • InChI=1S/C19H27NO3/c1-13(2)15-8-10-16(11-9-15)18(21)20-17(19(22)23)12-14-6-4-3-5-7-14/h3-7,13,15-17H,8-12H2,1-2H3,(H,20,21)(H,22,23)/t15-,16-,17-/m1/s1 check
  • Key:OELFLUMRDSZNSF-BRWVUGGUSA-N check
 ☒check (what is this?)  (verify)

Nateglinide belongs to the meglitinide class of blood glucose-lowering drugs.

PharmacologyEdit

Nateglinide lowers blood glucose by stimulating the release of insulin from the pancreas. It achieves this by closing ATP-dependent potassium channels in the membrane of the β cells. This depolarizes the β cells and causes voltage-gated calcium channels to open. The resulting calcium influx induces fusion of insulin-containing vesicles with the cell membrane, and insulin secretion occurs.

ContraindicationsEdit

Nateglinide is contraindicated in patients who:

  • have known hypersensitivity to the compound or any ingredient in the formulation.
  • are affected with type 1 (namely insulin-dependent) diabetes mellitus.
  • are in diabetic ketoacidosis.

Comparisons with other drugs for type 2 diabetesEdit

A study funded by Novo Nordisk, the U.S. distributor for Repaglinide, compared their product with Nateglinide in "A randomized, parallel-group, open-label, multicenter 16-week clinical trial".[1] They concluded that the two were similar, but "repaglinide monotherapy was significantly more effective than nateglinide monotherapy in reducing HbA1c and FPG values after 16 weeks of therapy."

DosageEdit

Nateglinide is delivered in 60 mg & 120 mg tablet form.

This article uses material from the Wikipedia article
 Metasyntactic variable, which is released under the 
Creative Commons
Attribution-ShareAlike 3.0 Unported License.